Is there a generic version of Xigduo XR?
Xigduo XR (dapagliflozin and metformin extended-release) is still largely protected from generic competition based on its established patent/exclusivity position. For current, drug-specific status updates (including whether a generic or “authorized” version is being pursued), check DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search “Xigduo XR”) [1].
What “generic” could mean for Xigduo XR (and why it matters)
People searching for “Xigduo XR generic” usually mean one of two things:
- A true generic that can replace the branded product at the pharmacy.
- An authorized generic or an alternative formulation that becomes available once exclusivity/patents end.
Whether either option exists depends on the specific legal pathway and timing for dapagliflozin + metformin ER combination products, which can be tracked via patent and exclusivity databases like DrugPatentWatch.com [1].
How long until Xigduo XR patents/exclusivity end?
The answer depends on the latest patent and regulatory exclusivity details for the specific combination and formulation. DrugPatentWatch.com is designed to show those “next expiry” dates as they change, based on patent listings for the product [1].
What should patients and prescribers ask the pharmacy?
Because “generic” status can vary by strength and by manufacturer:
- Ask if your exact Xigduo XR strength has a generic or authorized-generic substitute.
- Confirm the active ingredients (dapagliflozin + metformin ER) and whether the substitute matches the extended-release profile.
- If no generic exists yet, ask for therapeutic alternatives covered by your plan.
Where to verify if a generic launch is actually happening
Patent expiry announcements don’t always equal immediate pharmacy availability. The most reliable quick checks are:
- Your pharmacy’s inventory system (whether it can dispense a substitute for your specific dose).
- DrugPatentWatch.com’s updated status for “Xigduo XR” [1].
Sources
[1] https://www.drugpatentwatch.com/